Patents by Inventor Jingwu Duan

Jingwu Duan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Barbituric acid derivatives as inhibitors of TNF-? converting enzyme (TACE) and/or matrix metalloproteinases
    Patent number: 6936620
    Abstract: The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, W, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as TNF-? converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: August 30, 2005
    Assignee: Bristol Myers Squibb Company
    Inventors: Jingwu Duan, Zhonghui Lu
  • Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
    Publication number: 20050182082
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Application
    Filed: January 13, 2005
    Publication date: August 18, 2005
    Inventors: Jingwu Duan, James Sheppeck, Bin Jiang, John Gilmore
  • Modulators of the glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof
    Publication number: 20050176716
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Application
    Filed: January 13, 2005
    Publication date: August 11, 2005
    Inventors: Jingwu Duan, Bin Jiang, James Sheppeck, John Gilmore
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20050171096
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Application
    Filed: March 30, 2005
    Publication date: August 4, 2005
    Inventors: James Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 6906053
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: June 14, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 6890915
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: May 10, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 6884806
    Abstract: The present application describes novel bicyclic lactam derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein A, B, C, D, R1, and R2 are defined in the present specification, which are useful as metalloprotease, TNF-?, and/or aggrecanase inhibitors.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: April 26, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carl P. Decicco, Ying Song, Jingwu Duan, Matthew E. Voss
  • MATRIX METALLOPROTEINASE INHIBITORS
    Publication number: 20050025702
    Abstract: Thus the present invention describes novel compounds comprising: 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in treatment of diseases associated with MMPs.
    Type: Application
    Filed: February 14, 2001
    Publication date: February 3, 2005
    Inventors: Carl Decicco, David Nelson, John Barrett, Alan Carpenter, Jingwu Duan, Milind Rajopadhye
  • Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
    Publication number: 20040254231
    Abstract: The present invention provides compounds of Formula (I): 1
    Type: Application
    Filed: June 2, 2004
    Publication date: December 16, 2004
    Inventors: Jingwu Duan, Chu-Biao Xue, James Sheppeck, Bin Jiang, Lihua Chen
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20040209874
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: May 12, 2004
    Publication date: October 21, 2004
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20040162426
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: February 13, 2004
    Publication date: August 19, 2004
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-&agr; converting enzyme (TACE)
    Patent number: 6770647
    Abstract: The present application describes to novel bicyclic hydroxamates derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, B1, B2, R1, and C are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: August 3, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James E. Sheppeck, Jingwu Duan
  • Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE)
    Publication number: 20040132693
    Abstract: The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: December 18, 2003
    Publication date: July 8, 2004
    Applicant: Bristol-Myers Squibb Pharma Company
    Inventors: Gregory R. Ott, Xiao Tao Chen, Jingwu Duan, Matthew E. Voss
  • Cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6743807
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 1, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco, Zhonghui Lu, Thomas P. Maduskuie, Jr., Chu-Biao Xue
  • Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- &agr; converting enzyme (TACE)
    Patent number: 6740649
    Abstract: The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR1, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: May 25, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory R. Ott, Xiao-Tao Chen, Jingwu Duan, Zhonghui Lu
  • Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20040072802
    Abstract: The present application describes novel &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: October 9, 2002
    Publication date: April 15, 2004
    Inventors: Jingwu Duan, Bryan W. King, Carl Decicco, Thomas P. Maduskuie, Mathew E. Voss
  • Spiro-cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr; converting enzyme (TACE)
    Patent number: 6720329
    Abstract: The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), and/or aggrecanase inhibitors.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: April 13, 2004
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: Gregory R. Ott, Xiao Tao Chen, Jingwu Duan, Matthew E. Voss
  • Amide derivatives as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase
    Patent number: 6689771
    Abstract: The present application describes novel amides and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: February 10, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Carl P. DeCicco, David J. Nelson, Chu-Biao Xue
  • Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases
    Publication number: 20030229084
    Abstract: The present application describes novel barbituric acid derivatives of formula I: 1
    Type: Application
    Filed: December 17, 2002
    Publication date: December 11, 2003
    Inventors: Jingwu Duan, Bin Jiang, Lihua Chen, Zhonghui Lu, Joseph Barbosa, William J. Pitts
  • Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
    Publication number: 20030225054
    Abstract: This invention relates to a method of treating inflammatory diseases in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one TACE inhibitor of Formula (I), (II), (III), or (IV) of the present invention or a stereoisomer or pharmaceutically acceptable salt form thereof, (ii) one or more anti-inflammatory agents selected from the group consisting of: selective COX-2 inhibitors, interleukin-1 antagonists, dihydroorotate synthase inhibitors, p38 MAP kinase inhibitors, TNF-&agr; inhibitors, TNF-&agr; sequestration agents, and methotrexate. The invention also relates to compositions and kits containing the same.
    Type: Application
    Filed: June 3, 2003
    Publication date: December 4, 2003
    Inventor: Jingwu Duan